Liquid Filling Machine Validation Parameters: Fill Limits, 17 Tests

Updated 11 September 2026 · By Darshan Singh, former QC Head, QA Head and Plant Head · Reviewed against primary pharmacopoeial and GMP texts

What is Liquid Filling Machine Validation?

Liquid filling machine validation is the documented process of proving that a filling line, alone or as part of an integrated liquid manufacturing system, consistently fills containers within predefined specifications and protects the product’s quality attributes, including sterility and container closure integrity where they apply, throughout routine production. The objective is to show that the equipment, operated under defined conditions, repeatedly delivers conforming product over time.

Every major GMP framework asks for the same thing in different words. WHO’s guidelines on validation (TRS 1019, Annex 3) set out qualification and validation as a lifecycle, with a dedicated appendix on qualification [9]. In the US, 21 CFR 211.68(a) requires automatic and mechanical equipment to be “routinely calibrated, inspected, or checked according to a written program” [10], and FDA’s process validation guidance describes the three-stage lifecycle of process design, process qualification and continued process verification [7]. For sterile lines, the revised EU GMP Annex 1, published in August 2022 and in operation from 25 August 2023, adds the contamination control strategy (CCS) as the frame around every filling decision [11].

Qualification vs validation

• Equipment qualification (DQ, IQ, OQ, PQ) is about the machine and its utilities: that the design meets GMP, that it is installed as designed, that it operates across its specified ranges, and that it performs with production materials or qualified substitutes under normal operating conditions [6].
• Process validation is about the whole manufacturing process, including equipment, utilities, methods and people, and whether it consistently produces product meeting its predetermined quality attributes [7].

For a liquid filling line the two overlap. Equipment qualification feeds process validation, and inspectors expect both to be tied together in the site’s validation master plan. Explore the basic requirements for process validation exercises if you are writing the process side of that plan.

Types of Liquid Filling Machines Used in Pharma

The dosing principle decides what the worst case is, which parts drift, and therefore which challenges an OQ must contain. A peristaltic filler and a piston filler can both hit the same target volume and still need quite different qualification protocols.

Swipe tables sideways on a phone.

If you are specifying a new oral liquid section rather than qualifying an existing one, the pharma machinery list for tablet, capsule and liquid sections covers the equipment set around the filler.

Critical Validation Parameters for Liquid Filling Machines

A liquid line is a chain of stations, and each one can make or break a container. The diagram numbers the stations of a typical oral liquid or small-volume parenteral line; the explorer below it shows what to verify at each station, and the table after that is the full parameter list with the basis of each acceptance criterion, which is the column most protocols leave out.

The 17 parameters, with the basis of each acceptance criterion

Every limit in a qualification protocol comes from somewhere: a pharmacopoeia, a regulation, the machine’s own design specification, or a decision the site made. Auditors ask which. The badges answer that question before it is asked: compendial regulatory design spec site-defined

Where a row says site-defined, the protocol must state how the number was derived. That derivation is what an inspector reads.

Fill Volume Acceptance Criteria: Pharmacopoeia vs Your OQ Limit

Fill limits come in layers, and mixing them up is the most common error on this topic, in published articles as well as in protocols. The graphic below separates them.

Schematic, not to scale. The overfill zone applies where a pharmacopoeia or regulation prescribes excess volume, as it does for US injectables.

Layer 1: the compendial tests, by dosage form

The table quotes The International Pharmacopoeia (WHO) because its text is free to verify from the primary source. For injections, ICH Q4B Annex 2(R1) declares the Ph. Eur. 2.9.17, JP 6.05 and USP <1> “Volume in container” texts interchangeable in the ICH regions and states that their acceptance criteria are the same [3]; confirm the Ph. Eur. or USP wording against your licensed edition before citing it. Where a national pharmacopoeia text could not be retrieved from a primary source, the row says so instead of carrying a number.

Two further Ph. Int. statements belong in every oral liquid filling protocol. In-process controls during the manufacture of oral liquids “should include pH and fill volume”, and for a single-dose oral liquid, development must demonstrate that the nominal content can be withdrawn from the container [2]. For injections, Ph. Int. allows the volume to be calculated as mass divided by density, which is how most lines run their fill checks [1].

Layer 2: regulatory overfill

For injectables in vials and ampoules sold in the US, 21 CFR 201.51(g) treats the declared quantity as the minimum and requires the variation above it to comply with the excess volume prescribed by the USP [4]. FDA’s manual of policies and procedures for reviewers states that, because of that regulation, the USP <1151> excess-volume recommendations “are considered requirements” [5]. The excess-volume table itself is USP text; take the values from the official edition.

Layer 3: the site in-process band, and how to derive yours

1. Start from the floor. The label claim, or the compendial minimum for the dosage form, plus any required overfill.
2. Measure your own process. From OQ data, estimate the standard deviation of each head separately. A 12-head filler is 12 processes, not one.
3. Set the target from the floor and the spread. Place the target far enough above the floor that the one-sided capability against the floor meets the minimum your quality system has set. The calculator below does the arithmetic.
4. Set the upper limit from container capacity, headspace, cost of giveaway and, for US injectables, the excess-volume recommendations.
5. Write the derivation into the protocol, with the data it came from. A band that can be traced to the floor, the spread and the target is a defensible band; a band copied from an article is not.

SQC of the Filling Process: Sampling, Control Charts and Cpk

Statistical quality control (SQC) of a filling process answers two questions with the same data: is the line stable, and is it capable of staying clear of the floor? Stability is a control-chart question; capability is a Cp and Cpk question. Both are answered per head.

• Sample by head, not by line. Pooling heads hides a single drifting piston behind eleven good ones. Label every sample with its head number.
• Individuals and moving-range chart. For one result at a time, NIST gives the individuals chart limits as the mean plus or minus 3 × (average moving range ÷ 1.128) [12]. A point outside those limits is a signal to investigate before it becomes an under-filled container.
• Capability. Cp = (USL − LSL) ÷ 6σ and Cpk = the smaller of (USL − mean) and (mean − LSL), each divided by 3σ [13]. Both assume the data are normally distributed [13]; check that before quoting either.
• Use the one-sided index against the floor. Because the compendial requirement for injections is a floor, the capability that matters for patient-facing compliance is Cpl = (mean − floor) ÷ 3σ. Cp and Cpk against your site band describe cost and control, not compliance.
• What Cpk to require. No pharmacopoeia sets one. NIST notes that Cpk should be at least 1.0 [13]; 1.33 is a common industry convention. Whichever you choose, it is site-defined and must be written into the VMP.

Process parameters for a bottle filling machine: monitoring and measurement

Design Qualification (DQ)

Annex 15 describes DQ as the stage where “the compliance of the design with GMP should be demonstrated and documented”, following a user requirements specification [6]. For a liquid filler, the URS is where most later OQ failures are either prevented or baked in.

• URS content that drives validation: product range (sterile or non-sterile, viscosity and foaming range), fill volumes and container formats, required fill accuracy and how it will be measured, speed range, cleaning concept (manual, CIP, SIP), automation level and data integrity requirements.
• Materials and hygienic design: product-contact materials specified and certified, surface finish suitable for cleaning, elastomers suitable for the product, no dead legs, full drainability.
• Sterile lines: compatibility with the RABS or isolator concept and with Grade A operation for filling and sealing [11]; connections for WFI, clean steam and process gases.
• Automation: role-based access, audit trail and secure data storage where electronic records will be used.
• FAT and SAT scope: Annex 15 expects equipment to be confirmed against the URS at the vendor site before installation where applicable [6]. Write the fill-accuracy test into the FAT, using your own containers.

Installation Qualification (IQ)

IQ confirms that the filler and its utilities are installed as designed [6]. Typical content:

• Equipment identification: model, serial number, tag numbers, location, matched to purchase documents and URS.
• Mechanical installation: levelling, anchoring, orientation, completeness; change parts identified and listed.
• Utilities: electrical supply, compressed air quality, nitrogen, vacuum, and for sterile lines WFI and clean steam, each verified against specification. The high-purity water system guide covers the WFI side.
• Instruments: every critical instrument installed with a valid calibration certificate and a place in the calibration programme [10].
• Drawings: as-built P&ID, general arrangement and wiring diagrams reconciled with the installation.
• Documents: manuals, material certificates, FAT and SAT reports, software version records, and draft SOPs for operation, cleaning and maintenance before OQ starts.

Common IQ deviations are missing as-built drawings, mislabelled utilities, uncalibrated instruments at hand-over and undocumented changes made during erection. Record each as a deviation, assess it, correct it and close it before OQ.

Operational Qualification (OQ)

Annex 15 asks OQ to include tests developed from knowledge of the process and equipment, and “tests to confirm upper and lower operating limits, and/or worst case conditions”. It also says a successful OQ should allow the operating and cleaning procedures, operator training and preventive maintenance requirements to be finalised [6]. For a liquid filler that means a test matrix, not a single run.

Record raw data at the point of measurement, individual fills and not just averages, with pass or fail against the stated criterion and a reference to any deviation. These records are read against ALCOA+ principles: attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring and available.

Performance Qualification (PQ)

Annex 15 describes PQ as tests using production materials, qualified substitutes or simulated product with equivalent behaviour, under normal operating conditions with worst-case batch sizes, with the sampling frequency justified [6]. In practice a liquid filler PQ adds what OQ cannot show: long runs, shift and operator changes, real product at real temperature, and the drift that only appears after hours of operation.

• Long-duration runs to capture pump or seal wear, tubing fatigue and thermal effects.
• Sampling at start, middle and end and after every stoppage or intervention, per head.
• Operator and shift variation across the PQ runs.
• Environmental monitoring integration on sterile lines, with aseptic process simulation handled in its own protocol. The aseptic processing control guide covers media fills.

How many batches? What each rulebook actually says

So “three batches” is a defensible default in an EU-facing file, and a number that must be justified by data in an FDA-facing one. For a multi-product syrup line, a bracketing or matrix approach that qualifies the worst-case viscosity and fill sizes for a product family can be justified; write the rationale into the protocol before the runs, not after.

Real-world PQ scenarios

• Sterile injectable line: PQ runs of vials on peristaltic heads in Grade A under RABS, with media fills qualified separately under the aseptic process simulation programme. Vial preparation upstream depends on a validated tunnel; see depyrogenation validation.
• Syrup filling machine validation: PQ of a high-viscosity oral syrup on a monoblock filler, covering fill weight per head at commercial speed, closure torque and label reconciliation. The syrup vs suspension QC guide explains why suspensions are the harder case for dose uniformity.
• Multi-product oral liquid line: worst-case products chosen by viscosity, foaming and fill size, with the bracketing logic documented and approved in advance.

Validation Documentation Requirements

Revised Schedule M requires the key elements of the qualification and validation programme to be “clearly defined and documented in a validation master plan” (Part I, 5.2) [8]. The document set for a filling line:

• Validation master plan, including the definition of PQ used at the site.
• URS, functional specification and traceability matrix linking every requirement to a DQ, FAT, SAT, IQ, OQ or PQ test.
• Approved DQ, IQ, OQ and PQ protocols with acceptance criteria and their basis, written before execution.
• Raw data: individual fill weights, calibration certificates of the balance and checkweigher, density and temperature records.
• Deviation and CAPA records linked to the tests that raised them.
• Final report with a clear statement of the qualified ranges: speeds, fill volumes, formats and products.
• Change control and requalification triggers: product, volume, speed, software, format parts, wear-part specifications. Annex 15 expects periodic evaluation at an appropriate frequency, with any fixed requalification period justified [6].

For why validation carries this weight in an inspection, see the importance of validation in a pharmaceutical company.

Regulatory Expectations and GMP Compliance

The frameworks converge on the lifecycle and differ on the details that end up in a protocol. Select a region.

Data integrity runs across all four: secure electronic and paper records, audit trails, access control and validated computerised systems. If the plant is preparing for a US inspection, the USFDA approval roadmap for Indian formulation plants sets the filling line in the wider programme.

Common Validation Failures and Industry Mistakes

• A fill limit cited to a pharmacopoeia that does not contain it. The ±% band is site-defined; say so and show the derivation.
• Sampling by line instead of by head. One worn piston averages away across a 12-head filler.
• Density taken at the wrong temperature, or a single density value used for the whole batch while product temperature changes, which shifts every calculated volume.
• OQ with water only, PQ with viscous product, and nothing in between. Bridge the two with a worst-case viscosity challenge or a documented rationale.
• Improper sampling plans: too few samples, no stratification across start, middle and end, no samples after stoppages.
• Inadequate challenge testing of alarms, interlocks and rejects, leaving robustness unproven.
• Missing or overdue calibration of the balance, checkweigher or load cells used to generate validation data.
• SOPs that do not match validated settings, so routine practice drifts from what was qualified.
• Vendor CIP/SIP cycles accepted without site studies on the actual manifold and product.

Risk-Based Validation Approach

ICH Q9(R1), adopted on 18 January 2023, lists failure mode and effects analysis among its risk management tools and adds a direct caution for anyone scoring an FMEA: risk scores, ratings and assessments should be based on an appropriate use of evidence, science and knowledge [16]. Use it to decide where validation effort goes: critical parameters get worst-case challenges and heavier sampling; low-risk functions get proportionate testing.

Apply the worst case to the highest and lowest fill volumes, the most viscous and most foaming products, the smallest and largest containers, and the minimum and maximum qualified speeds.

Example banding only. RPN bands are a site-defined convention, not an ICH requirement.

Two cautions. First, multiplying ordinal scores can hide a severity-10 failure mode behind a low RPN, so many quality systems add a rule that any high-severity item is treated as high risk regardless of RPN. Second, read detectability carefully: fill-volume errors are highly detectable by in-line checkweighing and in-process checks, which keeps their D score low, while failures such as a breached sterilising filter or a Grade A excursion are hard to detect in the finished unit, which is exactly why they need intensive validation.

Validation Checklist for Liquid Filling Machines

SOP: Liquid Filling Machine Qualification and Fill-Weight Verification

A template you can adapt. Header fields are left blank on purpose: a document number belongs to your quality system, not to this page.

Future Trends in Filling Machine Validation

The direction of travel is from one-time qualification to continuous evidence. FDA’s third stage of process validation, continued process verification, asks for ongoing assurance that the process stays in a state of control during routine production [7], and a modern filler already produces the data to show it:

• 100% in-line checkweighing and per-head trending, turning the fill-weight record from periodic samples into a continuous control chart.
• SCADA and MES integration, with electronic batch records and automated trend review that must themselves be validated.
• Predictive maintenance on tubing, seals and pistons, driven by the same per-head drift data that the SQC section uses.

Frequently Asked Questions

References

1. World Health Organization. The International Pharmacopoeia. 13th ed. Geneva: WHO; 2025. 5.6 Extractable volume for parenteral preparations. Available from: https://digicollections.net/phint/pdf/b/7.5.7.5.6-Extractable-volume-for-parenteral-preparations.pdf. Accessed September 2026.
2. World Health Organization. The International Pharmacopoeia. 13th ed. Geneva: WHO; 2025. Liquid preparations for oral use. Available from: https://digicollections.net/phint/pdf/b/6.2.1.2.Liquid-preparation-for-oral-use.pdf. Accessed September 2026.
3. International Council for Harmonisation. Q4B Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions. Annex 2(R1): Test for extractable volume of parenteral preparations general chapter. Silver Spring (MD): US Food and Drug Administration; September 2017. Available from: https://www.hhs.gov/guidance/sites/default/files/hhs-guidance-documents/FDA/Q4B-Annex-2–Test-for-Extractable-Volume-of-Parenteral-Preparations-General-Chapter.pdf. Accessed September 2026.
4. Code of Federal Regulations. Title 21, Section 201.51: Declaration of net quantity of contents, paragraph (g). Washington (DC): Office of the Federal Register. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.51. Accessed September 2026.
5. US Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Quality. MAPP 5019.1 Rev. 1: Allowable excess volume/content in injectable drug and biological products. Effective 28 January 2022. Available from: https://www.fda.gov/media/155066/download. Accessed September 2026.
6. European Commission. EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Annex 15: Qualification and validation. Brussels; 2015 (in operation 1 October 2015). Available from: https://health.ec.europa.eu/system/files/2016-11/2015-10_annex15_0.pdf. Accessed September 2026.
7. US Food and Drug Administration. Guidance for industry. Process validation: general principles and practices. Revision 1. Silver Spring (MD): FDA; January 2011. Available from: https://www.fda.gov/media/71021/download. Accessed September 2026.
8. Ministry of Health and Family Welfare, Government of India. Drugs Rules, 1945: Schedule M (revised), Good manufacturing practices and requirements of premises, plant and equipment for pharmaceutical products. G.S.R. 922(E), 28 December 2023. The Gazette of India: Extraordinary. Available from: https://cdsco.gov.in/opencms/opencms/en/Notifications/Gazette-Notifications/. Accessed September 2026.
9. World Health Organization. Good manufacturing practices: guidelines on validation. WHO Technical Report Series, No. 1019, Annex 3. Geneva: WHO; 2019. Available from: https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/production/trs1019-annex3-gmp-validation.pdf. Accessed September 2026.
10. Code of Federal Regulations. Title 21, Section 211.68: Automatic, mechanical, and electronic equipment. Washington (DC): Office of the Federal Register. Available from: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211/subpart-D/section-211.68. Accessed September 2026.
11. European Commission. EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice. Annex 1: Manufacture of sterile medicinal products. Brussels; 22 August 2022 (in operation 25 August 2023; point 8.123 from 25 August 2024). Available from: https://health.ec.europa.eu/system/files/2022-08/20220825_gmp-an1_en_0.pdf. Accessed September 2026.
12. National Institute of Standards and Technology. NIST/SEMATECH e-Handbook of Statistical Methods. Section 6.3.2.2: Individuals control charts. Gaithersburg (MD): NIST. Available from: https://www.itl.nist.gov/div898/handbook/pmc/section3/pmc322.htm. Accessed September 2026.
13. National Institute of Standards and Technology. NIST/SEMATECH e-Handbook of Statistical Methods. Section 6.1.6: What is process capability? Gaithersburg (MD): NIST. Available from: https://www.itl.nist.gov/div898/handbook/pmc/section1/pmc16.htm. Accessed September 2026.
14. US Food and Drug Administration. Guidance for industry. Sterile drug products produced by aseptic processing: current good manufacturing practice. Rockville (MD): FDA; September 2004. Available from: https://www.fda.gov/media/71026/download. Accessed September 2026.
15. World Health Organization. WHO good manufacturing practices for sterile pharmaceutical products. WHO Technical Report Series, No. 1044, Annex 2. Geneva: WHO; 2022. Available from: https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/production/trs1044-annex-2-gmp-for-sterile-pharmaceutical-products.pdf. Accessed September 2026.
16. International Council for Harmonisation. ICH guideline Q9(R1): Quality risk management. Adopted 18 January 2023. Geneva: ICH; 2023. Available from: https://database.ich.org/sites/default/files/ICH_Q9(R1)_Guideline_Step4_2022_1219.pdf. Accessed September 2026.

Technical and educational content only; not legal, medical or investment advice. Pharmacopoeial texts, GMP guidelines and Indian statutory instruments change between editions. Verify every limit against the edition in force for your product and market before use. Values marked “check source” are deliberately not reproduced because the primary text could not be verified from a freely available official source.